<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9836">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05689203</url>
  </required_header>
  <id_info>
    <org_study_id>QLS1128-201</org_study_id>
    <nct_id>NCT05689203</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic&#xD;
      Participants With Mild to Moderate COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2022</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to sustained recovery of COVID-19 symptoms</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>The time from the start of treatment to the time when 11 COVID-19 symptoms get scores of 0 for three consecutive days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to sustained alleviation of COVID-19 symptoms</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>The time from the start of treatment to the time when the severity of 11 COVID-19 symptoms downgrade for three consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained recovery/ alleviation of each COVID-19 symptoms</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>The time from the start of treatment to the time when each COVID-19 symptoms get scores of 0 for three consecutive days,or the severity of each COVID-19 symptoms downgrade for three consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained recovery/ alleviation/exacerbation of first COVID-19 symptoms</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>The time from the start of treatment to the time when first COVID-19 symptoms get scores of 0 for three consecutive days,or the severity of first COVID-19 symptoms downgrade for three consecutive days,or the severity of first COVID-19 symptoms deteriorate for two consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>Changes of viral load compared to the baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time when the virus first turn negative and the proportion of patients that the virus turn negative</measure>
    <time_frame>Baseline through Day 15</time_frame>
    <description>The time when the virus first turn negative and the proportion of patients that the virus turn negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality, COVID-19 related mortality</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>All-cause mortality, COVID-19 related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Adverse events</measure>
    <time_frame>Baseline through Day 29</time_frame>
    <description>TEAEs associated with drug,SAE associated with drug, adverse events leading to withdrawal, vital signs, physical examination, laboratory examination, 12-lead electrocardiogram, etc</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>QLS1128</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QLS1128 will be administered orally for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching to QLS1128 will be administered orally for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLS1128</intervention_name>
    <description>dose 1</description>
    <arm_group_label>QLS1128</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLS1128</intervention_name>
    <description>dose 2</description>
    <arm_group_label>QLS1128</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects between ages of 18-80 years.&#xD;
&#xD;
          2. Confirmed SARS-CoV-2 infection as determined by RT-PCR or antigen test in any specimen&#xD;
             collected within 48 hours prior to randomization，first diagnosis of this infection&#xD;
             within 72 hours prior to the randomization.&#xD;
&#xD;
          3. Initial onset of the COVID-19-related symptoms/signs within 48 hours prior to the&#xD;
             randomization，and at least 1 of the COVID-19-related symptoms/signs (Cough,Shortness&#xD;
             of breath or difficulty breathing,fever,Chills,Body pain or muscle&#xD;
             pain,Diarrhea,Nausea,Vomiting，Headache，Sore throat，Stuffy or runny nose)present on the&#xD;
             day of randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with QLS1128 sustained-release tablets or other 3CL protease&#xD;
             inhibitors failed.&#xD;
&#xD;
          2. Has received local approved anti-SARS-CoV-2 drugs within 7 days before screening or&#xD;
             plan to receive them during the study period (e.g. paxlovid, azvudine, etc.)&#xD;
&#xD;
          3. Has received monoclonal antibody against SARS-CoV-2 virus within 1 year prior to&#xD;
             screening.&#xD;
&#xD;
          4. Has received or expect to receive convalescent plasma therapy for COVID-19 patients&#xD;
             during the trial.&#xD;
&#xD;
          5. Has received any CYP3A4/2C8 strong inducer within 28 days prior to screening or plan&#xD;
             to receive any CYP3A4/2C8 strong inducer during the study period.&#xD;
&#xD;
          6. A known history of active liver disease , including acute/chronic hepatitis B,&#xD;
             hepatitis C, cirrhosis, or acute liver failure.&#xD;
&#xD;
          7. Allergic or have contraindications to test drugs or test drug excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>yunfei ju, M.D.</last_name>
    <phone>15053185458</phone>
    <email>yunfei.ju@qilu-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qilu Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yunfei ju, M.D.</last_name>
      <phone>15053185458</phone>
      <email>yunfei.ju@qilu-pharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 15, 2023</study_first_submitted>
  <study_first_submitted_qc>January 15, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>January 15, 2023</last_update_submitted>
  <last_update_submitted_qc>January 15, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

